GSK plc (LON:GSK) Receives GBX 1,917.86 Consensus PT from Brokerages

Shares of GSK plc (LON:GSK) have received an average recommendation of “Hold” from the seven brokerages that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is GBX 1,917.86.

GSK has been the subject of several recent research reports. Shore Capital Group reiterated a “buy” rating and issued a GBX 2,300 price target on shares of GSK in a research report on Wednesday, February 4th. Deutsche Bank Aktiengesellschaft raised their price objective on GSK from GBX 1,600 to GBX 1,675 and gave the company a “hold” rating in a research note on Thursday, January 15th. UBS Group reissued a “neutral” rating and set a GBX 1,940 target price on shares of GSK in a research report on Friday, January 23rd. JPMorgan Chase & Co. restated an “underweight” rating on shares of GSK in a research report on Wednesday, January 7th. Finally, Citigroup boosted their target price on GSK from GBX 1,900 to GBX 2,250 and gave the company a “buy” rating in a research report on Monday, February 9th.

GSK Trading Down 0.1%

GSK stock opened at GBX 2,223.16 on Tuesday. The firm has a fifty day moving average price of GBX 1,923 and a 200 day moving average price of GBX 1,724.42. GSK has a fifty-two week low of GBX 1,242.50 and a fifty-two week high of GBX 2,282. The firm has a market cap of £89.70 billion, a PE ratio of 16.72, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81.

GSK (LON:GSK) last released its quarterly earnings data on Wednesday, February 4th. The company reported GBX 172 EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Sell-side analysts anticipate that GSK will post 175.980975 earnings per share for the current fiscal year.

Insider Buying and Selling at GSK

In other GSK news, insider Luke Miels sold 15,579 shares of the company’s stock in a transaction dated Friday, February 13th. The shares were sold at an average price of GBX 2,160, for a total value of £336,506.40. Also, insider Wendy Becker acquired 3,334 shares of the company’s stock in a transaction that occurred on Friday, February 20th. The stock was purchased at an average cost of GBX 2,219 per share, for a total transaction of £73,981.46. Insiders purchased a total of 7,931 shares of company stock valued at $16,480,489 in the last three months. Company insiders own 0.20% of the company’s stock.

Key Headlines Impacting GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: Investor confidence boost — IBD upgraded GSK’s ADR, a technical/fundamental endorsement that can attract momentum and retail buying. GSK ADR earns IBD stock rating upgrade
• Positive Sentiment: Insider buying — independent director Wendy Becker purchased 3,334 shares at ~GBX 2,219, signaling management/board conviction. Insider purchases often support sentiment. GSK Director Wendy Becker Increases Stake with Share Purchase
• Positive Sentiment: Ongoing buybacks — GSK repurchased 470,000 shares (~£10.5m) recently, modestly supporting EPS and indicating capital return. GSK lifts treasury stake with latest £10.5m share buyback
• Positive Sentiment: Clinical/commercial upside — a real‑world study reported AREXVY (RSV vaccine) is associated with lower risks of heart attack, stroke and severe COPD/asthma exacerbations, which could bolster uptake and long‑term revenue. GSK’s AREXVY Associated With Reductions in Certain RSV-Related Risks
• Positive Sentiment: R&D partnerships — GSK struck multi‑year collaborations with Jackson Laboratory / NYSCF to advance human cellular models and neurodegenerative research, strengthening its pipeline in high‑value areas. These are longer‑term positives for drug discovery. GSK strikes 5-year deal with Jackson Laboratory
• Neutral Sentiment: Trading activity — options activity has spiked on NYSE listings, indicating speculative interest and short‑term volatility rather than a directional fundamental change. GSK Sees Options Surge in NYSE Composite
• Neutral Sentiment: Analyst/market discussion — some market pieces question whether GSK’s recent rally limits upside, which can cool momentum even amid positive fundamentals. Is It Too Late To Consider GSK After Its Strong Share Price Rally?
• Negative Sentiment: Insider selling — former CEO Luke Miels sold 15,579 shares recently; large director/exec sales can weigh on sentiment even if they’re for personal reasons. Luke Miels Sells 15,579 Shares of GSK Stock

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.